Literature DB >> 19373034

Novel mechanisms of HIV protease inhibitor resistance.

Monique Nijhuis1, Noortje M van Maarseveen, Jens Verheyen, Charles Ab Boucher.   

Abstract

PURPOSE OF REVIEW: Several alternative mechanisms that cause protease inhibitor resistance have been proposed. A summary of the proposed mechanisms and the status regarding their clinical relevance is given. RECENT
FINDINGS: At this moment only changes in the cleavage sites of protease (either alone or in the background of protease mutations) have been associated with phenotypic changes in IC50 and virological failure.
SUMMARY: Further studies are necessary to unravel the mechanism, the clinical relevance and potential effect of transmission of these cleavage site changes.

Year:  2008        PMID: 19373034     DOI: 10.1097/COH.0b013e3283136cd9

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  5 in total

1.  Selection of drug-resistant feline immunodeficiency virus (FIV) encoding FIV/HIV chimeric protease in the presence of HIV-specific protease inhibitors.

Authors:  Ying-Chuan Lin; Meaghan Happer; John H Elder
Journal:  J Virol       Date:  2013-05-29       Impact factor: 5.103

2.  Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity.

Authors:  Noortje M van Maarseveen; Dan Andersson; Martin Lepšík; Axel Fun; Pauline J Schipper; Dorien de Jong; Charles A B Boucher; Monique Nijhuis
Journal:  Retrovirology       Date:  2012-04-01       Impact factor: 4.602

3.  Long-term treatment outcomes of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who experienced NRTI and NNRTI failure.

Authors:  Weerawat Manosuthi; Supeda Thongyen; Samruay Nilkamhang; Sukanya Manosuthi; Somnuek Sungkanuparph
Journal:  AIDS Res Ther       Date:  2012-03-13       Impact factor: 2.250

4.  HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat.

Authors:  Axel Fun; Noortje M van Maarseveen; Jana Pokorná; Renée Em Maas; Pauline J Schipper; Jan Konvalinka; Monique Nijhuis
Journal:  Retrovirology       Date:  2011-08-24       Impact factor: 4.602

5.  Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure.

Authors:  Weerawat Manosuthi; Sasisopin Kiertiburanakul; Wannarat Amornnimit; Wisit Prasithsirikul; Supeda Thongyen; Samruay Nilkamhang; Kiat Ruxrungtham; Somnuek Sungkanuparph
Journal:  AIDS Res Ther       Date:  2009-12-23       Impact factor: 2.250

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.